HealthVerity Valuation, Funding & Investors

HealthVerity is valued at $721M as of June 2021.

Last HealthVerity valuation

$721M

Series D · Jun 2021

Last HealthVerity funding round

$100M

Series D · Jun 2021

Cumulative funding HealthVerity raised

$142M

across 4 funding rounds

Key investors in HealthVerity

  • Greycroft
  • Flare Capital Partners
  • Foresite Capital
  • Durable Capital Partners

HealthVerity Overview

About HealthVerity

HealthVerity is a healthcare data technology company enabling providers, pharmaceutical manufacturers, hospitals, and payers to integrate patient data from diverse sources. Its identity resolution and matching tools support interoperable data exchange while maintaining privacy protections. Headquartered in Philadelphia, Pennsylvania, and founded in 2014, HealthVerity facilitates rapid dataset creation for analytics and insights across the healthcare sector.


Founded

2014

HQ

United StatesPhiladelphia, PA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$721M (Jun 2021)

HealthVerity Valuation

HealthVerity is currently valued at $721M, based on its Series D in June 2021.

The $100M round was led by Durable Capital Partners, with participation from Flare Capital Partners, Greycroft and Foresite Capital.

HealthVerity valuation by funding round

HealthVerity valuation by funding round
DateStageValuation
Jun 2021Series D$721M

HealthVerity Funding History

HealthVerity has raised a total of $142M across 4 funding rounds.

HealthVerity's first fundraising round was a $7M Series A in April 2016. The most recent completed round was a $100M Series D in June 2021.

HealthVerity funding rounds

HealthVerity funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jun 2021Series DDurable Capital Partners (lead); Flare Capital Partners; Greycroft; Foresite Capital$100M$721MHealthVerity is a healthcare technology company offering the IPGE (Identity, Privacy, Governance, and Exchange) platform, which provides a centralized database of de-identified real-world data including electronic records, lab tests, medical claims, and health information from U.S. patients. The platform supports secure data exchange for life sciences, payers, government agencies, pharma, and over 250 healthcare organizations, enabling uses like clinical trial recruitment, patient matching, and research analytics through partnerships with health systems, payers, and labs. On June 28, 2021, HealthVerity closed a $100 million Series D funding round led by Durable Capital Partners, with participation from existing investors Flare Capital Partners, Foresite Capital, and Greycroft. This brought total funding to approximately $143-146 million across five rounds. Proceeds fund platform expansion, new partnerships to grow the data ecosystem, commercialization efforts, and scaling patient identity resolution technology amid rising demand during the pandemic. The round valued HealthVerity at a post-money valuation of $720.55 million, as reported for the Series D. Headcount doubled to about 150 employees by mid-2021, reflecting growth in its privacy-minded data marketplace for pharma and insurance. HealthVerity serves top pharmaceutical companies for detailed patient insights in studies and competes in real-world data platforms, with comparables like Aetion. An IPO was considered but not imminent, with founders noting favorable healthcare IT valuations provided optionality. The investment aligns with Durable's focus on compounding companies in healthcare data governance.
Apr 2019Series CForesite Capital (lead); Flare Capital Partners; Greycroft$25M-HealthVerity, founded in 2014 and based in Philadelphia, PA, operates a cloud-based marketplace platform that enables the discovery, licensing, and linking of de-identified patient data from top-tier providers including medical claims, pharmacy claims, lab results, EMR, genetic results, and device data. The platform serves buyers such as pharmaceutical manufacturers, hospitals, payers, and retail pharmacies, as well as data providers seeking to control licensing for research. In April 2019, HealthVerity raised $25 million in a Series C funding round led by Foresite Capital, with participation from Flare Capital Partners, Greycroft Partners, and other existing investors. The funds were allocated to support continued growth, investment in the technology platform, and go-to-market activities. Prior to the Series C, HealthVerity achieved significant traction in 2018, expanding its customer base to over 100 top pharmaceutical manufacturers, health insurance payers, pharmaceutical services firms, and healthcare services organizations. Foresite Capital's CEO Jim Tananbaum highlighted the company's role in solving data organization, linking, and licensing challenges to enhance patient insights. HealthVerity continued its growth trajectory post-Series C, raising subsequent rounds including a $100 million Series D in June 2021 led by Durable Capital Partners with participation from existing investors Flare Capital Partners, Foresite Capital, and Greycroft, bringing total funding to approximately $146 million across five rounds. The Series D supported scaling of its IPGE (Identity, Privacy, Governance, and Exchange) platform, expansion of its real-world data ecosystem, and advancements in patient identity resolution technology amid increasing demand from over 250 healthcare enterprises and 80% of top pharmaceutical companies.
Apr 2017Series BFlare Capital Partners (lead); Greycroft (lead)$10M-HealthVerity is a Philadelphia-based cloud platform for the discovery, licensing, and linking of HIPAA-compliant, de-identified healthcare data. The company provides pharmaceutical manufacturers, healthcare providers, and payers with tools to build bespoke datasets from over thirty national healthcare data suppliers, covering medical claims, prescription claims, lab results, electronic medical records, and other data types on more than 300 million individuals in the United States. In May 2017, HealthVerity closed a $10 million Series B financing round led by Flare Capital Partners and Greycroft Partners, with participation from Foresite Capital and additional strategic healthcare investors. The funding was earmarked for expansion of the company's healthcare data ecosystem, advanced privacy solutions, and data interoperability technologies. The company had launched HealthVerity Marketplace, enabling customers to rapidly build and license datasets meeting the requirements of commercial analytics and real-world evidence solutions.
Apr 2016Series AFlare Capital Partners (lead); Greycroft$7M-HealthVerity is a cloud-based platform for the discovery, licensing, and linking of healthcare data, serving pharmaceutical companies, insurance payers, and healthcare organizations. The company developed privacy-minded technology tools to help customers discover and integrate optimal patient data sets, enabling rapid assembly of data from diverse healthcare sources for research and analytics purposes. In April 2016, HealthVerity closed a Series A funding round of $7.1 million led by Flare Capital Partners and Greycroft Partners, with participation from additional strategic healthcare investors. The funding was deployed to advance the company's privacy and data interoperability technologies. Board additions from the round included Michael Greeley of Flare Capital, Rachel Winokur (Greycroft advisor), and Matt Wallach, co-founder of Veeva Systems.

Who has invested in HealthVerity?

4 investors have backed HealthVerity across its funding rounds, including Greycroft, Flare Capital Partners, Foresite Capital and Durable Capital Partners.

Lead investors include Durable Capital Partners, Foresite Capital, Flare Capital Partners and Greycroft.


HealthVerity Investors

Investors in HealthVerity by funding rounds participated
InvestorHQRoundsRoleFirst check
Flare Capital PartnersUnited StatesBoston, MA4LeadApr 2016
GreycroftUnited StatesNew York City, NY4LeadApr 2016

This data is available for Pro users. Sign up to see all 4 HealthVerity investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by HealthVerity

HealthVerity has acquired 2 companies to date.

Last acquisition by HealthVerity was on May 4th 2026. HealthVerity acquired Symphony Health Solutions for undisclosed valuation.


Latest Acquisitions by HealthVerity

Symphony Health Solutions
Curisium
Description
Symphony Health Solutions is a Conshohocken-headquartered healthcare analytics firm delivering integrated datasets on physician prescribing, patient journeys, pharmacy dispensing, payer reimbursements, and sales performance. Acquired by ICON plc in 2021, its longitudinal data covers the full market lifecycle from predictive sizing to compensation optimization for pharmaceutical and life sciences clients.
Curisium is a healthcare services firm offering revenue cycle management and contracting software for hospitals. Its platform automates payer negotiations and compliance in the US market. Headquartered in Nashville, it targets mid-sized providers since its 2015 founding.
HQ CountryUnited StatesUnited States
HQ City
Phoenix, AZ
Los Angeles, CA
Deal Date4 May 202620 Jul 2020
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all HealthVerity acquisitions and their M&A valuation multiples.

Start Free Trial

HealthVerity Competitors

HealthVerity competitors include listed companies like Veradigm, Yidu Tech and Indegene, and private ones like Arine, Truveta and Medbanks.

Public and private companies comparable to HealthVerity
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
VeradigmUnited StatesUnited StatesPublicly listed$588M$54M$523M0.9x
ArineUnited StatesSan Francisco, CAPrivate--$520M-
TruvetaUnited StatesSeattle, WAPrivate--$1B-
Yidu TechChinaChinaPublicly listed$122M($4M)$449M1.2x
MedbanksChinaBeijingPrivate--$430M-
IndegeneIndiaIndiaPublicly listed$366M$68M$1.5B3.3x

HealthVerity Public Comps

HealthVerity is still privately-owned, but its public comps include SOPHiA Genetics, B-Soft Co., Phreesia, Sphere, Hangzhou Pinming Software, Craneware, Weave Communications, RaySearch Labs, MedicalSystem Technology and HealthStream.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
SOPHiA Genetics$77M($65M)8.8x7.5x(10.4x)(18.8x)
B-Soft Co.$157M($37M)4.7x4.8x(20.0x)(20.0x)
Phreesia$481M$27M1.3x1.3x23.2x5.3x
Sphere$70M$6M14.3x6.9x156.3x103.0x
Hangzhou Pinming Software$65M$8M12.5x11.9x100.2x-
Craneware$206M$59M2.8x2.7x9.7x8.7x
Weave Communications$239M($13M)2.3x2.1x(44.4x)35.9x
RaySearch Labs$137M$59M4.4x4.2x10.1x9.3x

This data is available for Pro users. Sign up to see all HealthVerity competitors and their valuation data.

Start Free Trial

Common questions about HealthVerity

When was HealthVerity founded?HealthVerity was founded in 2014.
Where is HealthVerity headquartered?HealthVerity is headquartered in Philadelphia, PA, United States.
Is HealthVerity publicly listed?No, HealthVerity is a private, VC-backed company.
What is HealthVerity's valuation?HealthVerity was last valued at $721M in its Series D in June 2021.
How much funding has HealthVerity raised?HealthVerity has raised $142M across 4 funding rounds.
What was HealthVerity's last funding round?HealthVerity's last funding round was a $100M Series D in June 2021, led by Durable Capital Partners.
Who are HealthVerity's investors?HealthVerity's investors include Flare Capital Partners, Greycroft, Foresite Capital and Durable Capital Partners.
Which companies are comparable to HealthVerity?Companies comparable to HealthVerity include Veradigm, Arine, Truveta, Yidu Tech, Medbanks and Indegene.
How many companies has HealthVerity acquired?HealthVerity has acquired 2 companies, including Symphony Health Solutions and Curisium.

See companies similar to HealthVerity

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial